Report from Annual General Meeting of Vitrolife AB (publ)

At Vitrolife’s Annual General Meeting yesterday, April 27, the following, amongst other things, was decided:

• The Board’s proposed dividend of SEK 2.60 per share for the financial year 2016 was approved. Tuesday May 2, 2017 was adopted as the record day. 

• Re-election of Board members Carsten Browall, Barbro Fridén, Tord Lendau, Pia Marions, Fredrik Mattsson and Jón Sigurdsson, in accordance with the election committee’s proposal. Carsten Browall was re-elected Chairman of the Board.     
       
• Re-election of Deloitte AB as the Company’s auditor for a mandate period of 3 years

• Remuneration to the members of the Board shall be totalling SEK 1,615,000, of which SEK 500,000 to the Chairman of the Board, SEK 175,000 to each of the other members of the Board, SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee and SEK 30,000 to the other members of these committees.

• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 2,170,000 shares in total, corresponding to just below 10 percent of the company’s share capital.

• The Board was authorized to take a decision, up until the next Annual General Meeting and on one or more occasions, with regard to the acquisition of the company’s own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.

• The proposed principles for remuneration and other conditions of employment for the senior management were approved. 

Gothenburg, April 28, 2017
VITROLIFE AB (publ)
The Board

Contact:
Carsten Browall, Chairman of the Board, phone 46 (0)70 255 65 32
Mikael Engblom, CFO, phone 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on April 28, 2017. 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife has approximately 350 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags: